Skip to main content

Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma

Trial Status: Active

This trial will study two treatment combinations for classical Hodgkin lymphoma (cHL). This trial will find out if these two treatment combinations work to treat cHL. It will also find out what side effects occur. A side effect is anything the drug does besides treating cancer. This study will have three parts (Parts A, B, and C). The drugs used in Part A are a combination of targeted anticancer drug (brentuximab vedotin) and three chemotherapy drugs (doxorubicin, vinblastine, and dacarbazine). These four drugs are called "A+AVD." Participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment (12 doses). Part A will look at whether the A+AVD drug combination reduces the number of participants who experience the side effect of febrile neutropenia. Febrile neutropenia is a very low white blood cell count and a fever, which can be life threatening. Parts B and C will use drug combination of brentuximab vedotin, plus nivolumab, doxorubicin, and dacarbazine. These four drugs are called "AN+AD." Parts B and C will study how well the drugs work to treat cHL and what side effects they cause.

Inclusion Criteria

  • Inclusion Criteria - Treatment-naïve, classic Hodgkin lymphoma (cHL) participants - Participants enrolling in Part A of the study must have Ann Arbor Stage III or IV disease - Participants enrolling in Part B of the study must have Ann Arbor Stage II with bulky mediastinal disease, or Stage III or IV - Participants enrolling in Part C of the study must have Ann Arbor Stage I or II with non-bulky mediastinal disease - Histologically confirmed cHL according to the current World Health Organization (WHO) Classification - Bidimensional measurable disease as documented by PET/CT or CT imaging - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 Exclusion Criteria - Nodular lymphocyte predominant HL - History of another malignancy within 3 years of the first dose of study drug or any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk or metastasis or death. Participants with nonmelanoma skin cancer, localized prostate cancer, or carcinoma in situ of any type are not excluded if they have undergone complete resection - Prior immunosuppressive chemotherapy, therapeutic radiation, or any immunotherapy within 12 weeks of the first study drug dose, unless underlying disease has progressed on treatment - Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways - Active cerebral/meningeal disease related to the underlying malignancy - Any active Grade 3 or higher viral, bacterial, or fungal infection within two weeks of the first dose of study drug (Grade 3 defined by the National Cancer Institute's Common Terminology Criteria for Adverse Events, NCI CTCAE Version 4.03) - Current therapy with other systemic anti-neoplastic or investigational agents - Planned consolidative radiotherapy (Parts B and C only) - Active interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity (Parts B and C only) - Grade 3 or higher pulmonary disease unrelated to underlying malignancy - Idiopathic interstitial pneumonia or diffusing capacity of the lung for carbon monoxide <50% predicted - History of a cerebral vascular event within 6 months of first dose of study drug - Child-Pugh B or C hepatic impairment - Grade 2 or higher peripheral sensory or motor neuropathy - Participants with acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive therapy as treatment or as prophylaxis against GvHD - Previous treatment with brentuximab vedotin - Participants who are pregnant or breastfeeding - Other serious condition that would impair the participant's ability to receive or tolerate the planned treatment and follow-up

Ohio

Cleveland
Case Comprehensive Cancer Center
Status: ACTIVE

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: IN_REVIEW

This study will have three parts. Part A of the study is designed to evaluate the incidence of febrile neutropenia, efficacy, and dose intensity in participants with advanced stage classical Hodgkin lymphoma (cHL) receiving granulocyte colony stimulating factor primary prophylaxis (G-PP) administration during treatment with frontline A+AVD. In Part A, participants will be treated with granulocyte colony stimulating factor (G-CSF) following every dose of A+AVD for 6 cycles of treatment. Participants will be treated using institutional standard of care practices for the majority of treatment decisions. Part B is designed to evaluate the combination of brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) as frontline treatment in participants with advanced cHL. In Part B, participants will be given AN+AD combination for 6 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage II with bulky mediastinal disease and Stage III or IV cHL. Part C is designed to evaluate AN+AD as frontline treatment in participants with early stage cHL. In Part C, participants will be given AN+AD combination for 4 cycles of treatment. This part of the trial will look at whether this combination of drugs is effective and tolerable in participants with Stage I or II cHL with non-bulky mediastinal disease.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Seattle Genetics

  • Primary ID SGN35-027
  • Secondary IDs NCI-2018-01922
  • Clinicaltrials.gov ID NCT03646123